Réglementation et droit · 21/09/20001 min de lecture
Prospective Grant of an Exclusive License: Treatment of Gaucher Disease
Traduction automatique locale · Langue originale de la source
Résumé
This is notice in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of a worldwide exclusive license to practice the inventions embodied in the patents and patent applications referred to below to BioPrime, Inc. of New York, New York. The patents and patent applications to be licensed are: U.S. Patent 5,705,153 issued January 6, 1998, "Glycolipid enzyme-polymer conjugates"; U.S. Patent 5,620,884 issued April 17, 1997, "Glycolipid enzyme-polymer conjugates"; U.S. Patent 5,879,680 issued March 9, 1999, "Cloned DNA for Synthesizing Unique Glucocerebrosidase"; U.S. Patent 6,074,864 issued June 13, 2000, "Cloned DNA for Synthesizing Unique Glucocerebrosidase"; and U.S. Patent Application 09/173,207 filed October 15, 1998, "DNA Sequencing Surrounding the Glucocerebrosidase Gene". Related cases include all continuation applications, divisional applications, continuation-in- part applications, and foreign counterpart applications related to the above.